New Clinical Trial: Assessment of Femoral Failure Load and Fracture Risk in Rare Bone Disorders Using MEKANOS Tool. Case Study of Fibrous Dysplasia of Bone/McCune Albright Syndrome (NCT07507942)
WHY IT MATTERS
This trial addresses a critical gap in fibrous dysplasia care—doctors currently lack reliable tools to predict which patients will experience fractures, making this the first systematic assessment of fracture risk in this population.
Researchers in France are studying a new tool called MEKANOS that measures how strong bones are and predicts fracture risk in people with fibrous dysplasia, a rare bone disease. This clinical trial involves 20 patients and aims to solve a major problem doctors face: they currently have no good way to know which patients are at highest risk of bone breaks. The study could help doctors make better treatment decisions for this condition.
NCT ID: NCT07507942 Status: ACTIVE_NOT_RECRUITING Conditions: Fibrous Dysplasia/McCune-Albright Syndrome Enrollment: 20 Sponsor: Hospices Civils de Lyon Summary: The issue of rare diseases has become a public health priority. In France, a national plan for rare diseases was published in 2004. It leads to the creation and certification of numerous Rare Disease Reference Centers by the French National Authority for Health (Haute Autorité de Santé). Our Fibrous Dysplasia Reference Center has been certified since 2006. However, evaluating the mechanical strength and fracture risk of fibrous dysplasia lesions remains a major unresolved challenge for clinicia
ASK YOUR DOCTOR
If you have fibrous dysplasia or McCune-Albright syndrome, ask your doctor whether this trial at the Lyon Rare Disease Reference Center might be relevant to your care, or whether similar fracture risk assessments are available at your treatment center.